A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function

British Journal of Clinical Pharmacology

Volumn 62, Issue 3, 2006, Pages 297-303

  Viberg, Anders ^a   Lannergård, Anders ^b   Larsson, Anders ^b   Cars, Otto ^b   Karlsson, Mats O ^a   Sandström, Marie ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cefuroxime; Cystatin C; NONMEM; Pharmacokinetics

Indexed keywords

BIOLOGICAL MARKER; CEFUROXIME; CYSTATIN C;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; COMPARTMENT MODEL; COVARIANCE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DETERMINATION; DRUG EXCRETION; GLOMERULUS FILTRATION; HUMAN; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; POPULATION MODEL; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CEFUROXIME; CYSTATIN C; CYSTATINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 33747053686     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02652.x     Document Type: Article

References (26)

1. Cars O. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997; 27: 29-33.
2. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998; 35: 391-402.
3. Bundtzen RW, Toothaker RD, Nielson OS, Madsen PO, Welling PG, Craig WA. Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays. Antimicrob Agents Chemother 1981; 19: 443-9.
4. Sanchez E, Evora CM, Torres A, Llabres M. A new approach to pharmacokinetic parameters: estimation of cefuroxime during haemodialysis. Biopharm Drug Dispos 1990; 11: 107-20.
5. Broekhuysen J, Deger F, Douchamps J, Freschi E, Mal N, Neve P, Parfait R, Siska G, Winand M. Pharmacokinetic study of cefuroxime in the elderly. Br J Clin Pharmacol 1981; 12: 801-5.
6. Foord RD. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother 1976; 9: 741-7.
7. Gower PE, Dash CH. The pharmacokinetics of cefuroxime after intravenous injection. Eur J Clin Pharmacol 1977; 12: 221-7.
8. van Dalen R, Vree TB, Hafkenscheid JC, Gimbrere JS. Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency. J Antimicrob Chemother 1979; 5: 281-92.
9. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ. Applied Therapeutics - The Clinical Use of Drugs, 8th edn. Baltimore, MD: Lippincott Williams & Wilkins 2005.
10. Lubran MM. Renal function in the elderly. Ann Clin Lab Sci 1995; 25: 122-33.
11. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933-53.
12. Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A. Structure and expression of the human cystatin C gene. Biochem J 1990; 268: 287-94.
13. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996; 56: 409-14.
14. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.
15. Hallberg P, Melhus H, Hansson LO, Larsson A. Cystatin C vs creatinine as markers of renal function in patients on digoxin treatment. Ups J Med Sci 2004; 109: 247-53.
16. Hoppe A, Seronie-Vivien S, Thomas F, Delord JP, Malard L, Canal P, Chatelut E. Serum cystatin C is a better marker of topotecan clearance than serum creatinine. Clin Cancer Res 2005; 11: 3038-44.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Viberg A, Sandstrom M, Jansson B. Determination of cefuroxime in human serum or plasma by liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 707-10.
19. Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004; 64: 25-30.
20. Beal SL, Sheiner LB. NONMEM Users Guide. San Fransisco: NONMEM Project Group, University of California 1994.
21. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Meth Programs Biomed 1999; 58: 51-64.
22. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001; 28: 231-52.
23. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21: 735-50.
24. Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer 2002; 38: 11-6.
25. Koot MJ, IJdenberg FN, Stuurman RM, Poell J, Bras LJ, Langemeijer JJ, Lie-A-Huen L. High pressure liquid chromatographic analysis of the serum concentration of cefuroxime after an intravenous bolus injection of cefuroxime in patients with a coronary artery bypass grafting. Pharm Weekbl Sci 1992; 14: 360-4.
26. Walstad RA, Nilsen OG, Berg KJ. Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. Eur J Clin Pharmacol 1983; 24: 391-8.